X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19547) 19547
Newsletter (496) 496
Magazine Article (184) 184
Book Chapter (106) 106
Newspaper Article (104) 104
Dissertation (29) 29
Publication (14) 14
Web Resource (11) 11
Streaming Video (8) 8
Transcript (7) 7
Book / eBook (6) 6
Book Review (6) 6
Conference Proceeding (4) 4
Reference (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12667) 12667
proton pump inhibitors (11522) 11522
male (6580) 6580
female (6073) 6073
gastroenterology & hepatology (5027) 5027
middle aged (4694) 4694
proton pump inhibitors - therapeutic use (4017) 4017
adult (3923) 3923
aged (3630) 3630
omeprazole (3438) 3438
pharmacology & pharmacy (3202) 3202
proton pump inhibitor (2904) 2904
treatment outcome (2657) 2657
gastroesophageal reflux - drug therapy (2334) 2334
risk factors (2231) 2231
helicobacter pylori (2201) 2201
gastroesophageal reflux (2135) 2135
helicobacter infections - drug therapy (1984) 1984
lansoprazole (1928) 1928
animals (1891) 1891
proton pump inhibitors - adverse effects (1805) 1805
therapy (1670) 1670
anti-ulcer agents - therapeutic use (1645) 1645
drug therapy, combination (1629) 1629
medicine, general & internal (1540) 1540
proton pump inhibitors - administration & dosage (1487) 1487
risk (1399) 1399
aged, 80 and over (1341) 1341
care and treatment (1336) 1336
medicine & public health (1269) 1269
omeprazole - therapeutic use (1244) 1244
2-pyridinylmethylsulfinylbenzimidazoles (1231) 1231
hydrogen-ion concentration (1193) 1193
retrospective studies (1156) 1156
gastroesophageal reflux disease (1136) 1136
research (1121) 1121
omeprazole - analogs & derivatives (1119) 1119
proton-pump inhibitors (1118) 1118
gastroesophageal-reflux disease (1109) 1109
anti-bacterial agents - therapeutic use (1108) 1108
adolescent (1090) 1090
health aspects (1090) 1090
management (1090) 1090
prospective studies (1081) 1081
disease (1043) 1043
abridged index medicus (1040) 1040
double-blind (1025) 1025
time factors (1003) 1003
drug therapy (991) 991
rabeprazole (991) 991
histamine h2 antagonists - therapeutic use (983) 983
pantoprazole (975) 975
surgery (966) 966
gastroesophageal reflux - diagnosis (959) 959
infection (944) 944
diagnosis (940) 940
prevalence (939) 939
young adult (929) 929
drug interactions (924) 924
gastroenterology (911) 911
gastroesophageal reflux - complications (889) 889
endoscopy (827) 827
esomeprazole (815) 815
helicobacter pylori - drug effects (812) 812
pharmacokinetics (790) 790
internal medicine (775) 775
proton pump inhibitors - pharmacology (757) 757
analysis (747) 747
symptoms (736) 736
anti-ulcer agents - administration & dosage (713) 713
dosage and administration (712) 712
omeprazole - administration & dosage (707) 707
oncology (699) 699
esophagitis (686) 686
medical research (684) 684
metaanalysis (679) 679
rats (675) 675
dose-response relationship, drug (673) 673
drug administration schedule (672) 672
efficacy (668) 668
proton pump (666) 666
clopidogrel (665) 665
eradication (661) 661
omeprazole - pharmacology (660) 660
prevention (653) 653
complications and side effects (651) 651
follow-up studies (645) 645
usage (641) 641
gastroenterology and hepatology (630) 630
helicobacter-pylori infection (624) 624
enzyme inhibitors - therapeutic use (622) 622
child (613) 613
anti-inflammatory agents, non-steroidal - adverse effects (608) 608
medicine, experimental (594) 594
biochemistry & molecular biology (587) 587
gerd (585) 585
nonsteroidal antiinflammatory drugs (584) 584
cancer (582) 582
clarithromycin (581) 581
helicobacter infections - microbiology (580) 580
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19014) 19014
Japanese (415) 415
German (316) 316
French (301) 301
Korean (256) 256
Russian (227) 227
Spanish (212) 212
Portuguese (81) 81
Chinese (65) 65
Czech (46) 46
Polish (46) 46
Hungarian (38) 38
Dutch (32) 32
Italian (29) 29
Norwegian (17) 17
Danish (14) 14
Finnish (9) 9
Ukrainian (9) 9
Romanian (7) 7
Slovak (6) 6
Turkish (6) 6
Swedish (5) 5
Icelandic (2) 2
Lithuanian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Indonesian (1) 1
Persian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2016, Volume 78, Issue 1, pp. 41 - 49
The Hedgehog pathway inhibitor vismodegib exhibits pH-dependent solubility, and in vitro studies have shown that vismodegib is a substrate of P-glycoprotein (P-gp... 
Medicine & Public Health | CYP inhibitors | Clinical pharmacology | Oncology | Cancer Research | Pharmacology/Toxicology | Clinical drug–drug interaction | Pharmacokinetic | Proton-pump inhibitor | P-glycoprotein inhibitor | SINGLE | HUMAN PLASMA | ORAL ABSORPTION | MASS-SPECTROMETRY | GDC-0449 | ONCOLOGY | Clinical drug-drug interaction | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | HEDGEHOG SIGNALING PATHWAY | SOLID-PHASE EXTRACTION | Fluconazole - pharmacology | Proton Pump Inhibitors - pharmacology | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Area Under Curve | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Fluconazole - administration & dosage | Solubility | Pyridines - pharmacokinetics | Anilides - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Itraconazole - pharmacology | Cytochrome P-450 CYP2C9 Inhibitors - administration & dosage | Cytochrome P-450 CYP2C9 Inhibitors - pharmacology | Drug Interactions | Anilides - administration & dosage | Proton Pump Inhibitors - administration & dosage | Rabeprazole - pharmacology | Female | Itraconazole - administration & dosage | Hydrogen-Ion Concentration | Rabeprazole - administration & dosage | Drug interactions | Cytochrome P-450 | Original
Journal Article
BMJ, ISSN 0959-8138, 01/2008, Volume 336, Issue 7634, pp. 2 - 3
...Proton pump inhibitors are one of the most frequently prescribed classes of drug in the world because they combine a high level of efficacy with low toxicity... 
Proton pumps | Prescription drugs | Dyspepsia | Primary health care | Hospital admissions | Proton pump inhibitors | Editorials | Drug prescriptions | State Medicine | Humans | United Kingdom | Practice Patterns, Physicians | Evidence-Based Medicine | Proton Pump Inhibitors - therapeutic use | Drug Prescriptions
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
...) inhibitor or a non-steroidal anti-inflammatory drug (NSAID) with a proton-pump inhibitor (PPI). These two treatments have similar effectiveness, but they are insufficient for protection of patients at very high risk for ulcer bleeding... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 02/2012, Volume 125, Issue 8, pp. 978 - 986
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 08/2013, Volume 128, Issue 8, pp. 845 - 853
BACKGROUND—Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease... 
dimethylarginine dimethylaminohydrolase | endothelium | proton pump inhibitors | nitric oxide | N,N dimethylarginine | N dimethylarginine | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | ENDOTHELIAL DYSFUNCTION | MYOCARDIAL-INFARCTION | NITRIC-OXIDE SYNTHASE | ACID SUPPRESSION | ADMA | DIMETHYLAMINOHYDROLASE DDAH | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | STAGE RENAL-DISEASE | ARTERY-DISEASE | Proton Pump Inhibitors - pharmacology | Humans | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Endothelium, Vascular - drug effects | Male | Arginine - analogs & derivatives | Esomeprazole - therapeutic use | Cardiovascular Diseases - epidemiology | Nitric Oxide Synthase Type III - metabolism | Gastroesophageal Reflux - drug therapy | Disease Models, Animal | Amidohydrolases - metabolism | Proton Pump Inhibitors - adverse effects | Cardiovascular Diseases - metabolism | Mice, Inbred C57BL | Risk Factors | Cells, Cultured | Biomarkers - blood | Proton Pump Inhibitors - therapeutic use | Animals | Lansoprazole - adverse effects | Endothelium, Vascular - metabolism | Arginine - blood | Lansoprazole - pharmacology | Endothelium, Vascular - pathology | Mice | Vasodilation - drug effects | Lansoprazole - therapeutic use | Gastroesophageal reflux | Complications and side effects | Usage | Care and treatment | Patient outcomes | Proton pump inhibitors | Cardiovascular diseases | Drug therapy | Health aspects | Risk factors
Journal Article